MedTrace Logo

The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia

NCT05172687 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 336460

Last updated 2024-02-13

No results posted yet for this study

Summary

This study aims to analyze how warning letters sent to physicians prescribing high levels of the antipsychotic quetiapine affected the health and quality of life of their patients with dementia. Using a randomized controlled trial conducted by the Centers for Medicare and Medicaid Services (CMS) in 2015, this secondary study looks at the effects of potential de-prescribing of antipsychotics by study physicians induced by the letters. The central question is whether the intervention led to better health and quality of life outcomes by encouraging more guideline-concordant care and whether changes in physicians' prescription behavior caused unintended harms.

Conditions

  • Alzheimer Disease
  • Dementia
  • Prescribing, Off-Label

Interventions

BEHAVIORAL

Overprescribing letter to attributed physician

Letter telling patient's attributed physician they were under review for high prescribing

BEHAVIORAL

Placebo letter to attributed physician

Letter to patient's attributed physician about unrelated Medicare regulation

Sponsors & Collaborators

  • National Bureau of Economic Research, Inc.

    collaborator OTHER

  • Harvard School of Public Health (HSPH)

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

  • Columbia University

    lead OTHER

Principal Investigators

  • Adam Sacarny, PhD · Columbia University

  • Michael L Barnett, MD, MS · Harvard School of Public Health (HSPH)

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05172687 on ClinicalTrials.gov